TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26936138

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (October-December to April-June)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Tanning
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Race/Ethnicity
Number of subjects: 426
Study: 25199824

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy (SMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home Exercise and Advice (HEA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication (MED)
Number of subjects: 0
Study: 22231041

Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (no triptorelin)
Number of subjects: 49
Study: 20576763

Group type: EXPERIMENTAL
Intervention: 2% topical ciclosporin A
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 17915119

Group type: EXPERIMENTAL
Intervention: Postal reminder on tetanus vaccination
Number of subjects: 622

Group type: COMPARATOR
Intervention: No action (control group)
Number of subjects: 622
Study: 15663445

Group type: EXPERIMENTAL
Intervention: slow‐speed bur and acid etching
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: air abrasion and acid etching
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: acid etching and application of a bonding agent
Number of subjects: 128

Group type: COMPARATOR
Intervention: slow‐speed prophylaxis brush followed by acid etching (control method)
Number of subjects: 128
Study: 12244290

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg and Ketamine 2 mg/kg (MK2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg and Ketamine 1 mg/kg (MK1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Midazolam 0.5 mg/kg (Control group M)
Number of subjects: 120
Study: 10397661

Group type: EXPERIMENTAL
Intervention: 5% acyclovir in a novel liposomal carrier (ethosome)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% acyclovir cream (Zovirax cream)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Drug-free vehicle
Number of subjects: 40
Study: 7577164

Group type: EXPERIMENTAL
Intervention: Bed rest for five days
Number of subjects: 9
Study: 2271366

Group type: EXPERIMENTAL
Intervention: Dilevalol (100-400 mg daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 389818

Group type: EXPERIMENTAL
Intervention: 1 g sulphamethizole twice daily
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim twice daily
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: 410 mg sulphadiazine plus 90 mg trimethoprim twice daily
Number of subjects: 1194

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim alone
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: 1 g sulphamethizole
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: 410 mg sulphadiazine plus 90 mg trimethoprim
Number of subjects: 1194
Study: 30869200

Group type: EXPERIMENTAL
Intervention: PrEP adherence reported via CASI
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Factors facilitating adherence
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Adherence barriers
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Future use intentions of PrEP
Number of subjects: 130
Study: 29016653

Group type: EXPERIMENTAL
Intervention: 400 IU/day vitamin D3 supplementation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin D3 supplementation
Number of subjects: 32
Study: 25504811

Group type: EXPERIMENTAL
Intervention: Biologic disease‐modifying antirheumatic drugs (DMARDs)
Number of subjects: 0
Study: 23688525

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PPSV23 after initial PCV13
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCV13 (re-vaccination for all adults aged 50-59)
Number of subjects: 100
Study: 21357275

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg once daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nifedipine 30 mg once daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 19134171

Group type: EXPERIMENTAL
Intervention: Phone counselling
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: E-mail counselling
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1386
Study: 17335962

Group type: EXPERIMENTAL
Intervention: Active magnetic stimulation (Neocontrol), 20 treatments of 20 minutes each over six weeks.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham therapy (identical looking/sounding device with deflector plate), 20 treatments of 20 minutes each over six weeks.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Active magnetic stimulation during cystometry.
Number of subjects: 44
Study: 14764129

Group type: EXPERIMENTAL
Intervention: Transvaginal electrical stimulation (TES)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (identical equipment but with no electrical current)
Number of subjects: 36
Study: 11301931

Group type: EXPERIMENTAL
Intervention: Empowerment educational model
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing educational model
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Helping People to Change educational model
Number of subjects: 15
Study: 9308642

Group type: COMPARATOR
Intervention: Standard blood components (not screened for CMV antibody)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: CMV-seronegative red cell (RBC) and platelet units
Number of subjects: 76
Study: 7959579

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatinum and 5-fluorouracil) and radiation followed by resection
Number of subjects: 69

Group type: COMPARATOR
Intervention: Resection alone
Number of subjects: 69
Study: 3311054

Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg t.i.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: colestyramine (4 g t.i.d.)
Number of subjects: 40
Study: 31559844

Group type: EXPERIMENTAL
Intervention: Fascial therapy (1 session per week for 3 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fascial therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 29530259

Group type: EXPERIMENTAL
Intervention: IBM targeting hostile interpretation bias (IBM‐H)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy video control (HVC)
Number of subjects: 40
Study: 28483774

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator (IV tPA) alone
Number of subjects: 0
Study: 25629321

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg (DexIV)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 8 mg (DexP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (30-mL bupivacaine 0.5% alone)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DexIV and DexP
Number of subjects: 75
Study: 23566943

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (7000 IU daily for 26 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 20931100

Group type: EXPERIMENTAL
Intervention: LOS 150 mg/HCTZ 25 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: LOS 150 mg/HCTZ 37.5 mg
Number of subjects: 105
Study: 18222735

Group type: EXPERIMENTAL
Intervention: Goshuyuto extract for 1 month, followed by 3 months of goshuyuto in the treatment group.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 3 months in the control group.
Number of subjects: 0
Study: 15973834

Group type: EXPERIMENTAL
Intervention: CSEB applied without any cavity preparation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CSEB applied after beveling enamel
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CSEB applied after etching enamel for 15 seconds with 35% phosphoric acid
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CSEB applied after beveling and etching enamel
Number of subjects: 34

Group type: COMPARATOR
Intervention: Overall results pooled from all groups
Number of subjects: 34
Study: 12796137

Group type: EXPERIMENTAL
Intervention: 22.5 Gy intravascular beta‐irradiation with rhenium-188 (n=113)
Number of subjects: 225

Group type: COMPARATOR
Intervention: No additional intervention (n=112)
Number of subjects: 225
Study: 10641044

Group type: EXPERIMENTAL
Intervention: Taiga Wurzel (ergospirometric study)
Number of subjects: 50
Study: 8846291

Group type: EXPERIMENTAL
Intervention: Sevoflurane (S group, n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Halothane (H group, n = 9)
Number of subjects: 19
Study: 1506461

Group type: EXPERIMENTAL
Intervention: Combined education and stress management program
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 6728094

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 micrograms/kg bodyweight/hour intravenously for 10 days, then orally for 4 days in diminishing dosages)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (9 patients not given Nimodipine)
Number of subjects: 27
Study: 31622292

Group type: EXPERIMENTAL
Intervention: Rush pin with long arm cast (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dynamic Compression Plate (Group A)
Number of subjects: 60
Study: 28499016

Group type: EXPERIMENTAL
Intervention: Banana-shaped cage
Number of subjects: 84

Group type: COMPARATOR
Intervention: Straight cage
Number of subjects: 84
Study: 26901353

Group type: EXPERIMENTAL
Intervention: 840 mg/day DHA
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 25105388

Group type: EXPERIMENTAL
Intervention: CS/PADM
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional bridged VHR
Number of subjects: 80
Study: 22569072

Group type: EXPERIMENTAL
Intervention: [¹⁵N]WP, [¹³C]Cas, and lactose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: [¹³C]WP, [¹⁵N]Cas, and lactose
Number of subjects: 18

Group type: COMPARATOR
Intervention: lactose alone
Number of subjects: 18
Study: 19148407

Group type: EXPERIMENTAL
Intervention: 4% titanium tetrafluoride solution (TiF4)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no TiF4)
Number of subjects: 10
Study: 17444584

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 16153511

Group type: EXPERIMENTAL
Intervention: Strain echocardiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age and hypertension
Number of subjects: 0
Study: 11823759

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg
Number of subjects: 24
Study: 10069545

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 51
Study: 9805071

Group type: EXPERIMENTAL
Intervention: Heberbiovac-HB vaccine at 10 g
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Heberbiovac-HB vaccine at 5 g
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Heberbiovac-HB vaccine at 2.5 g
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Overall reactogenicity for all groups
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Predominant symptoms
Number of subjects: 3
Study: 2032492

Group type: EXPERIMENTAL
Intervention: Autologous LAK cell reinfusion treatment for 6 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: 10% glucose solution intravenous drip for 6 weeks
Number of subjects: 64
Study: 7226903

Group type: EXPERIMENTAL
Intervention: High-dose theophylline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenoterol (10 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (130 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (130 mg) + fenoterol (5 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31827346

Group type: EXPERIMENTAL
Intervention: Complex response time (CRT) protocol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Simple response time (SRT) tests
Number of subjects: 47
Study: 30082324

Group type: EXPERIMENTAL
Intervention: Interrupted sitting (3 min of moderate-intensity walking at 80% of ventilatory threshold every 30 min for 3 h)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Prolonged sitting (3 h of continuous sitting)
Number of subjects: 35
Study: 26609969

Group type: EXPERIMENTAL
Intervention: Complex Contrast Training (CCT); N=10
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional Strength Training (TST); N=12
Number of subjects: 22
Study: 24606865

Group type: EXPERIMENTAL
Intervention: PCV13/PPSV23
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: PPSV23/PCV13
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: PCV13/PCV13
Number of subjects: 720

Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 720
Study: 22442396

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19081652

Group type: EXPERIMENTAL
Intervention: Arm A: Paclitaxel 200 mg/m2 and carboplatin AUC6 with accelerated radiotherapy 1.7 Gy BID to 64.6 Gy in 4.5 weeks.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Arm B: Daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy 2 Gy to 60 Gy in 6 weeks.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Arm C: Weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy.
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group not specified as there are three treatment arms.
Number of subjects: 151
Study: 17868210

Group type: EXPERIMENTAL
Intervention: Boiled extract of Nigella sativa (15 mL/kg of 0.1 g%)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 29
Study: 15115259

Group type: EXPERIMENTAL
Intervention: 25 mg of vitamin B6 daily and one monthly injection of 200 microg vitamin B12, plus 15 mg folic acid daily (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 100 mg of vitamin B6 daily and one monthly injection of 1,000 microg vitamin B12, plus 15 mg folic acid daily (group B)
Number of subjects: 50
Study: 11873639

Group type: EXPERIMENTAL
Intervention: Removal of drains on 2nd postoperative day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Removal of drains on 3rd postoperative day
Number of subjects: 100
Study: 9922064

Group type: EXPERIMENTAL
Intervention: Community outreach intervention conducted by indigenous lay health workers; 56 sessions on general prevention, 86 on cervical cancer, and 90 on breast cancer.
Number of subjects: 373

Group type: COMPARATOR
Intervention: Control group (women in Sacramento, California)
Number of subjects: 373
Study: 7483616

Group type: EXPERIMENTAL
Intervention: Magnesium (magnesium carbonate) 3 x 0.6
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Proajmaline (neogilurytmal) 3 x 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined treatment (neogilurytmal 2 x 20 mg and magnesium 2 x 0.6)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 3190993

Group type: EXPERIMENTAL
Intervention: Allopurinol 50 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allopurinol (various doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allopurinol (cessation)
Number of subjects: 8
Study: 123426

Group type: EXPERIMENTAL
Intervention: Leukocytic interferon with metacyl (0.25 ml once a day)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Leukocytic interferon with metacyl
Number of subjects: 213
Study: 31903299

Group type: EXPERIMENTAL
Intervention: Wound Conforming Matrix (WCM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 100
Study: 31076203

Group type: EXPERIMENTAL
Intervention: 500 μg of nemiralisib via Ellipta dry powder inhaler
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 750 μg of nemiralisib via Ellipta dry powder inhaler
Number of subjects: 12
Study: 29387128

Group type: EXPERIMENTAL
Intervention: Gongjindan (GJD) 3.75g orally once a day for 56 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (3.75g orally once a day for 56 days)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gongjindan (GJD)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 26964165

Group type: EXPERIMENTAL
Intervention: Acupuncture and isolated-ginger moxibustion
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg, twice a day for 1 month)
Number of subjects: 110
Study: 22924409

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily for 5 days (n = 48)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (n = 24)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg administered 24 h post-warfarin
Number of subjects: 72
Study: 22099889

Group type: EXPERIMENTAL
Intervention: Healthy Dads, Healthy Kids program
Number of subjects: 50

Group type: COMPARATOR
Intervention: 6-month wait-list control group
Number of subjects: 50
Study: 18294998

Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5 mg weekly)
Number of subjects: 4576

Group type: COMPARATOR
Intervention: Vitamin K antagonists (adjusted-dose, target INR 2-3)
Number of subjects: 4576
Study: 16943482

Group type: EXPERIMENTAL
Intervention: Minimally-invasive direct anterior approach
Number of subjects: 26

Group type: COMPARATOR
Intervention: Anterolateral transgluteal approach
Number of subjects: 26
Study: 12641543

Group type: EXPERIMENTAL
Intervention: Topical 5‐ASA 2 g and 80 mM L‐1 sodium‐butyrate bid (Group A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 5‐ASA 2 g and 80 mL saline bid (Group B)
Number of subjects: 51
Study: 10637255

Group type: EXPERIMENTAL
Intervention: ACE chemotherapy every 2 weeks with G-CSF support
Number of subjects: 403

Group type: COMPARATOR
Intervention: ACE chemotherapy every 3 weeks (control group)
Number of subjects: 403
Study: 9051172

Group type: EXPERIMENTAL
Intervention: Palumbo 'Dynamic Patellar Brace'
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cho‐Pat Knee Strap
Number of subjects: 59

Group type: COMPARATOR
Intervention: No brace
Number of subjects: 59
Study: 7908879

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no H2 receptor antagonist)
Number of subjects: 14
Study: 29758356

Group type: EXPERIMENTAL
Intervention: Expectation plus conditioning (E+C)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Expectation only (E‐only)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Conditioning only (C‐only)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Natural history (NH) control group
Number of subjects: 133
Study: 29094434

Group type: EXPERIMENTAL
Intervention: Web-based autonomy supports for 12 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Individual consultations on healthy lifestyle
Number of subjects: 71
Study: 26076136

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23841945

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) supplementation
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 19777535

Group type: EXPERIMENTAL
Intervention: Telecare management for pain and depression
Number of subjects: 405
Study: 18820040

Group type: EXPERIMENTAL
Intervention: Flip-flops
Number of subjects: 10

Group type: COMPARATOR
Intervention: Athletic shoes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bare feet
Number of subjects: 10
Study: 16417414

Group type: EXPERIMENTAL
Intervention: Bioavailable testosterone
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin (SHBG)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: SHBG and bioavailable testosterone (in the same model)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Other sex steroid levels (estrone, total estradiol, total testosterone)
Number of subjects: 623
Study: 12716250

Group type: EXPERIMENTAL
Intervention: THC (delta‐9‐tetrahydrocannabinol) up to 10 mg/day for 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10793162

Group type: EXPERIMENTAL
Intervention: Ventilation with lower tidal volumes (initial tidal volume of 6 ml per kilogram of predicted body weight, plateau pressure of 30 cm of water or less)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Traditional ventilation treatment (initial tidal volume of 12 ml per kilogram of predicted body weight, plateau pressure of 50 cm of water or less)
Number of subjects: 861
Study: 9489309

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg i.v.) administered immediately after induction and for postoperative analgesia beginning at skin closure
Number of subjects: 40

Group type: COMPARATOR
Intervention: No ketorolac administered before the operation, postoperative treatment same as intervention group
Number of subjects: 40
Study: 22290668

Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine in de-caffeinated coffee
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3-course meal (∼ 1300 calories)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no caffeine, no meal)
Number of subjects: 48
Study: 3899404

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 254

Group type: COMPARATOR
Intervention: Dipyridamole-aspirin
Number of subjects: 254

Group type: COMPARATOR
Intervention: Pentoxifylline-aspirin
Number of subjects: 254